Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups

Piao, Xuan‐Mei; Kim, Seon‐Kyu; Byun, Young Joon; Zheng, Chuang-Ming; Kang, Ho Won; Kim, Dong-Won; Kim, Yong‐June; Lee, Sang Cheol; Kim, Wun-Jae; Moon, Sung‐Kwon; Choi, Yung Hyun; Yun, Seok‐Joong

doi:10.3390/ijms232214481

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the degree of genomic modifications in NMIBC serves as a prognostic indicator for the likelihood of progression and recurrence, irrespective of other influencing factors; therefore, tumors displaying significant chromosomal instability need to be treated as high-risk category tumors, irrespective of their histopathological results [ 8 ]. A recent study suggested the effectiveness of the prognostic significance of the molecular signature-based subtype predictor (MSP888) and the authors compared its effectiveness to the risk scores of the 2021 EAU, CUETO, and EORTC [ 60 ]. MSP888 is based on molecular signatures, which consists of three distinct subtypes, MSP888 was proven to distinguish NMIBC patients with varied prognoses and responses to bacillus Calmette-Guérin (BCG) treatment in their previous study [ 61 ].…”

Section: Discussionmentioning

confidence: 99%

Molecular classification of urothelial bladder carcinoma

Schwarzova,

Varchulova Novakova,

Danisovic

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

Urothelial bladder carcinoma (UC) ranks among the top ten most commonly diagnosed cancers worldwide on an annual basis. The standardized classification system for urothelial bladder tumors is the Tumor, Node, Metastasis classification, which reflects differences between non-muscle-invasive bladder carcinoma (NMIBC) and muscle-invasive bladder carcinoma (MIBC) and it depends on the extent to which tumor has infiltrated the bladder wall and other tissues and organs. NMIBC and MIBC exhibit great intrinsic heterogeneity regarding different prognoses, survival, progression, and treatment outcomes. In recent years, studies based on mRNA expression profiling revealed the existence of biologically relevant molecular subtypes of UC, which show variant molecular features that can provide more precise stratification of UC patients. Here, we present a complex classification of UC based on mRNA expression studies and molecular subtypes of NMIBC and MIBC in detail with regard to different mRNA expression profiles, mutational signatures, and infiltration by non-tumor cells. The possible impact of molecular subtyping on treatment decisions and patients’ outcomes is outlined, too.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular classification of urothelial bladder carcinoma

Schwarzova,

Varchulova Novakova,

Danisovic

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

show abstract

“…[22]. In addition, worse prognosis was found for the GU subtype compared to Uro, particularly in BCG (Bacillus Calmette-Guèrin) untreated patients where the effect size was similar to that of stage T1 compared to Ta (multivariable hazard ratios 6.0 and 6.7, respectively) [25].…”

Section: Progress Toward Clinical Applications Of Lundtaxmentioning

confidence: 99%

“…[22]. In addition, worse prognosis was found for the GU subtype compared to Uro, particularly in BCG (Bacillus Calmette‐Guèrin) untreated patients where the effect size was similar to that of stage T1 compared to Ta (multivariable hazard ratios 6.0 and 6.7, respectively) [25]. For muscle‐invasive bladder cancer, complete pathologic response to neoadjuvant cisplatin‐based chemotherapy occurred in 52% of GU but only 21% Ba/Sq cases [26].…”

Section: Progress Toward Clinical Applications Of Lundtaxmentioning

confidence: 99%

The Lund taxonomy for bladder cancer classification – from gene expression clustering to cancer cell molecular phenotypes, and back again

Höglund

Bernardo

Sjödahl

et al. 2023

The Journal of Pathology

View full text Add to dashboard Cite

Treatment of bladder cancer patients depends on precise diagnosis. Molecular subtyping by gene expression profiling may contribute substantially to subclassification of bladder cancer. Several classification systems have been proposed. Most of these base their classification on whole biopsy features, and molecular subtypes are therefore often defined by a combination of features from the cancer cells as well as infiltrating noncancer cells. This makes the link to what is seen at the cancer cell level unclear. The aim of the Lund taxonomy (LundTax) has been to align gene expression‐level classification with immunohistochemical classification to identify cancer cell phenotypes independent of infiltration and proliferation. A systematic approach was used in which gene expression clusters were validated and adjusted by immunohistochemistry using markers expressed only by the cancer cells. This review provides a rationale for defining molecular subtypes and a step‐by‐step description of the development of the LundTax with motivations for each modification and extension. As the cancer cell phenotype defined by gene expression profiling corresponds with the immunohistochemistry of cancer cells, the LundTax represents a harmonization of the gene expression and immunohistochemical levels. Furthermore, the classification system is independent of pathological stage and is, thus, applicable to all urothelial carcinomas. A unified classification system relevant for both the molecular biologist and pathologist will facilitate systematization of current treatment practices, as well as the development of new treatments. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

show abstract

“…However, it is di cult for physicians to provide personalized treatment and management strategies for patients based on current classi cation systems. For example, some patients who showed highly invasive biological characteristics and early metastasis were pathologically classi ed as low-risk classi cation (6).…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, muscleinvasive bladder cancer typically requires neoadjuvant chemotherapy, radical cystectomy (RC), postoperative systemic chemotherapy, or second-line immunotherapy (5). Intravesical BCG therapy is commonly used to reduce the risk of recurrence and progression after transurethral resection of bladder tumor (TURBT) for intermediate and high-risk non-muscle-invasive disease (3,6). However, approximately one-third of patients will progress to muscle-invasive stages, signi cantly decreasing cancer special survival (CSS) (7,8).…”

Section: Introductionmentioning

confidence: 99%

Identification of Model Based on Oxidative Stress-related Genes for Predicting Prognosis and Therapeutic Features in Bladder Cancer

Zhou*,

Huang*,

Luo

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Bladder cancer is one of the most common malignant tumors, presenting as a heterogenous entity that requires a severe stratified strategy to enhance clinical decision-making and patient counseling. Multiple studies have investigated the relationship between oxidative stress and tumor progression, highlighting its potential role in cancer pathogenesis. Herein, our study aimed to establish a prognostic model based on the oxidative stress-related gene for risk stratification in bladder cancer. Methods: Differentially expressed oxidative stress genes (oxidative stress DEGs) were identified using microarray and clinical data from the GEO database. Functional enrichment and survival analyses were performed in screened oxidative stress DEGs. A risk score model was constructed, and its diagnostic value and relationship with the prognosis as well as its sensitivity to chemotherapy and immunotherapy were verified through Cox regression, receiver operating characteristic curve and drug sensitivity analysis. The TCGA-BLCA cohort was set as the training cohort, GSE13507 and GSE32894 were used for external validation. A nomogram was constructed to facilitate the clinical application. Results: The risk score model demonstrated a significant difference in overall survival between the high- and low-risk groups. The area under the curve and hazard ratio revealed the independent prognostic value of the model. There are differences in the sensitivity of chemotherapy and immunotherapy between the high- and low-risk groups. Conclusions: Our findings provide a new prognostic model that can serve as a reliable reference for the prognosis and personalized therapy of patients with bladder cancer.

show abstract

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups

Cited by 5 publications

References 25 publications

Molecular classification of urothelial bladder carcinoma

Molecular classification of urothelial bladder carcinoma

The Lund taxonomy for bladder cancer classification – from gene expression clustering to cancer cell molecular phenotypes, and back again

Identification of Model Based on Oxidative Stress-related Genes for Predicting Prognosis and Therapeutic Features in Bladder Cancer

Contact Info

Product

Resources

About